Danaher Corporation (DHR)

Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central AfricaJune 29, 2026 8:30 AM
PR Newswire (US) WASHINGTON, June 29, 2026 /PRNewswire/ -- The Danaher Foundation, supported by Danaher Corporation (NYSE: DHR), today announced a $1 million commitment to support urgent, on-the-ground response to the Ebola Bundibugyo outbreak in the Democratic Republic of Congo (DRC) and Uganda through Save the Children, the International Rescue Committee (IRC) and the World Food Program USA in support of the World Food Programme (WFP).The funding will be distributed across the three organizations to enable rapid, flexible response to evolving conditions on the ground. Efforts will focus on critical needs including infection prevention, hygiene support, community-based health services and emergency food assistance— areas where speed and adaptability can directly save lives.Together, Save the Children, IRC and WFP bring complementary capabilities and deep operational presence to coordinate response efforts in some of the most affected communities. Their combined expertise allows resources to be directed quickly to where they are needed most as the situation continues to evolve."The Ebola outbreak is occurring in a highly fragile humanitarian environment, where years of underinvestment and recent global funding cuts have severely weakened health services," said Heather Reoch Kerr, IRC's Country Director for the Democratic Republic of Congo. "The IRC has extensive experience responding to Ebola and other infectious disease outbreaks in complex humanitarian settings. The support from the Danaher Foundation is critical to continue the IRC's response to the Ebola outbreak.""This generous support comes at a critical moment for communities in eastern DRC," said Barron Segar, President and CEO of World Food Program USA. "Containing Ebola requires speed, coordination and access, and this grant will help WFP move life-saving medical cargo, transport frontline responders and provide families affected by the outbreak with food assistance to help prevent this health crisis from sparking a deeper hunger emergency." "The Ebola outbreak is compounding an already dire humanitarian crisis in the DRC," said Greg Ramm, Save the Children's Country Director in the Democratic Republic of Congo. "For children, the stakes could not be higher—they urgently need access to basic healthcare and protection. We are deeply grateful for Danaher's partnership. Their support will help us deliver essential medical supplies, strengthen efforts to contain the spread of the disease, and ultimately save lives." According to the World Health Organization (WHO), more than 1,000 cases of Ebola Bundibugyo have been confirmed in the Democratic Republic of Congo, with cases now spreading to neighboring Uganda. Fewer than half of infections are currently diagnosed and traced, suggesting the outbreak may be larger than reported. Children under the age of 14 are particularly vulnerable and more than twice as likely to die after contracting Ebola.ABOUT EBOLA DISEASE
The Centers for Disease Control (CDC) defines Ebola as a disease caused by an infection with an orthoebolavirus found primarily in sub-Saharan Africa. Orthoebolaviruses can cause serious and often deadly disease, with a mortality rate as high as 80-90 percent. The 2026 Ebola outbreak is driven by the Bundibugyo virus disease (BVD), that causes a severe and often fatal form of Ebola disease. Declared a Public Health Emergency of International Concern by the WHO, the 2026 outbreak is historically the largest known Bundibugyo virus outbreak.ABOUT THE DANAHER FOUNDATION
The Danaher Foundation is the independent philanthropic arm of Danaher Corporation, a global life sciences and technology innovator. Through partnerships with trusted nonprofit organizations and communities around the world, the Foundation's work reflects Danaher's broader commitment to applying science, innovation, and collaboration to address urgent global needs.ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.  View original content:https://www.prnewswire.com/news-releases/danaher-foundation-commits-1-million-to-ebola-outbreak-relief-efforts-in-central-africa-302812644.htmlSOURCE Danaher Corporation Original: Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa

Danaher Schedules Second Quarter 2026 Earnings Conference CallJune 22, 2026 4:15 PM
PR Newswire (US) WASHINGTON, June 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You can access the conference call by dialing 833-419-0865, within the U.S. or +1 785-838-9333 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ226). A replay of the conference call will be available shortly after the conclusion of the call until August 4, 2026. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."Danaher's earnings press release, the webcast slides and other related materials will be posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings" beginning at 6:00 a.m. ET on the date of the earnings call and will remain available following the call.ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com. View original content:https://www.prnewswire.com/news-releases/danaher-schedules-second-quarter-2026-earnings-conference-call-302805847.htmlSOURCE Danaher Corporation Original: Danaher Schedules Second Quarter 2026 Earnings Conference Call

Danaher Completes Acquisition of Masimo CorporationJune 10, 2026 8:55 AM
PR Newswire (US) WASHINGTON, June 10, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has completed the acquisition of Masimo Corporation, a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings.Masimo's trusted brand, advanced sensor technology and AI-enabled patient monitoring bring complementary and powerful new capabilities to the Danaher diagnostics portfolio. As a result of the transaction, Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has ceased trading on the Nasdaq Stock Market. Masimo will continue to operate under the Masimo brand and will be a stand-alone operating company within Danaher's Diagnostics segment."Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo's growth and global reach," said Julie Sawyer Montgomery, Executive Vice President of Diagnostics at Danaher. "We are excited to welcome the Masimo team to Danaher."The consideration payable to former Masimo stockholders will be paid in accordance with the terms of the merger agreement, as further described in the definitive transaction materials filed with the U.S. Securities and Exchange Commission.Second Quarter and Full Year 2026 OutlookThere is no change to Danaher's previously communicated second quarter and full-year 2026 guidance range, excluding the expected contribution from Masimo. The Company does not expect a material contribution from Masimo in the second quarter of 2026. The Company intends to update full-year 2026 guidance in connection with its second quarter earnings release to incorporate Masimo's expected contribution.FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION
Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the second quarter and full year 2026, expected strengthening of the Company's ability to deliver differentiated products in acute care settings, expected acceleration of Masimo's growth and global reach, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we have incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and  military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2026.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com. View original content:https://www.prnewswire.com/news-releases/danaher-completes-acquisition-of-masimo-corporation-302796748.htmlSOURCE Danaher Corporation Original: Danaher Completes Acquisition of Masimo Corporation

Sirius XM Holdings Set to Join S&P MidCap 400June 8, 2026 6:09 PM
PR Newswire (US) NEW YORK, June 8, 2026 /PRNewswire/ -- Sirius XM Holdings Inc. (NASD: SIRI) will replace Masimo Corp. (NASD: MASI) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, June 11. S&P 500 & 100 constituent Danaher Corp. (NYSE: DHR) is acquiring Masimo in a deal expected to be completed soon pending final conditions.Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective
Date Index
Name Action Company Name Ticker GICS Sector  June 11, 2026  S&P MidCap 400 Addition Sirius XM HoldingsSIRI Communication Services  June 11, 2026  S&P MidCap 400 Deletion MasimoMASI Health Care ABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.FOR MORE INFORMATION:S&P Dow Jones Indices
index_services@spglobal.comMedia Inquiries
spdji.comms@spglobal.com View original content:https://www.prnewswire.com/news-releases/sirius-xm-holdings-set-to-join-sp-midcap-400-302794483.htmlSOURCE S&P Dow Jones Indices Original: Sirius XM Holdings Set to Join S&P MidCap 400

SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key CollaborationsJune 1, 2026 2:00 PM
Business Wire At ASMS, SCIEX, a Danaher company and leader in life science analytical technologies, introduced platform-wide advancements across its accurate mass ZenoTOF line. The updates include new SCIEX OS 5.0 software features, broader front-end compatibility, and forward-looking software collaborations designed to help omics researchers solve complex biological questions. This connected environment reduces workflow complexity, while enabling deeper, more actionable insights from a single, dynamic platform. SCIEX OS 5.0 software introduces new features including Central Metrics Tracker, Central Monitoring, Reporter Template Creator, an AI enabled “helpme” function, and AI enabled Calculated Columns. Additional ZenoTOF line specific advancements include: ZT Scan DIA 3.0 combines the completeness of data-independent acquisition with narrower Q1 isolation windows so researchers can balance selectivity, sensitivity, and throughput based on the requirements of the experiment. This technology underpins scalable proteomics and robust metabolomics, reducing workflow complexity and expanding the range of applications a single platform can address. With enhanced sensitivity mode on, the ZenoTOF 8600 system has demonstrated significant gains for low-input proteomics workflows with nanoflow, where improvements range from approximately 10% to 40% gains in both identification and quantitation. Expanded front-end compatibility boosts the flexibility of the ZenoTOF line. Echo® MS+ system integration with the ZenoTOF 8600 system is the industry’s highest-throughput accurate mass platform, sampling at up to 1 sample per second. It delivers enhanced sensitivity for high-throughput screening, making it a foundational screening technology to accelerate early discovery, reduce complexity and consumable costs. HDX-MS by Trajan Scientific and Medical brings deep automation expertise and comprehensive data processing, unlocking deeper insights into protein structure and binding. These bookends complement EAD on the ZenoTOF line to deliver an integrated end-to-end solution for routine high-sensitivity, zero-scrambling, amino-acid residue resolved HDX-MS. New source enhancements deliver seamless compatibility between Evosep, IonOpticks, and the ZenoTOF line. Researchers can now fully leverage Whisper Zoom methods—bringing together high sensitivity, robustness, and throughput in a unified SCIEX-based platform to accelerate next-generation proteomics analyses. In addition, an agreement between SCIEX and IonOpticks plans to expand access to advanced liquid chromatography solutions for the proteomics community, including Aurora XS columns. Key collaborations across leading software platforms enable researchers to operate within the workflows they already use and trust. A key collaboration brings BSI’s advanced AI-based proteomic PEAKS software data processing across the ZenoTOF line. It enables researchers to identify, quantify, and validate biomarkers in a single solution, and eliminates the traditional fragmentation between discovery and targeted quantitation, reducing complexity and improving reproducibility for translational research. MS-Dial becomes one of the pioneer collaborators translating ZT Scan DIA 3.0 measurements into life science answers. Customers can discover new biomarkers using this trusted life-sciences software package that profiles metabolomics and lipidomics. Collaboration with MZIO brings SCIEX data compatibility into mzmine, allowing users to integrate SCIEX into existing metabolomics and small molecule pipelines that support scalable data processing, advanced feature extraction, and downstream analysis across diverse MS workflows. “Ultimately, we are not just delivering incremental performance — but a step change in how researchers can move across the omics continuum. This is just the beginning. Our commitment is simple - continuous innovation in this dynamic platform delivers for customers, across workflows,” says Jose Castro-Perez, Vice President of Product Management at SCIEX. Learn more about the ZenoTOF line unlock at https://sciex.com/products/mass-spectrometers/qtof-systems/8600-system. ABOUT SCIEX SCIEX, a Danaher company and leader in life science analytical technologies, empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ? Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Advances in human wellness depend on the power of precise science.? For more information, visit sciex.com. ? Connect with us on LinkedIn, Facebook, and Instagram.? ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com. The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks). © 2026 DH Tech. Dev. Pte. Ltd. MKT-38539-A. View source version on businesswire.com: https://www.businesswire.com/news/home/20260601890868/en/ Lulu VanZandt
Senior Manager, Brand, Public Relations and Social Media

SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement ToolsJune 1, 2026 2:00 PM
Business Wire At ASMS, SCIEX, a Danaher company and leader in life science analytical technologies, launched the novus V55 system - a next-generation triple quadrupole mass spectrometer designed for the realities of high-pressure, results-driven labs. The system provides exceptional sensitivity and accelerated output, in a smaller footprint and with improved energy efficiency when compared to the SCIEX 5500+ system. This quantitative solution expands testing capabilities across pesticide and food analysis, pharmaceutical impurities, bioanalysis, PFAS testing and additional applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601916060/en/The novus V55 system from SCIEX. The novus V55 system is built for business and real-world impact. Key features include: aeMRM (accelerated MRM) can acquire up to 1,000 MRMs per second, which increases sample throughput, expands testing capabilities, and maintains quantitative accuracy. New SCIEX OS 5.0 software introduces new features including: Central Metrics Tracker allows for tracking of performance and assay level metrics. Central Monitoring shows instrument status across the fleet. Reporter Template Creator easily creates customized reports. AI enabled “helpme” function answers feature and functionality questions quickly using a natural language interface. AI enabled Calculated Columns creates custom calculations for columns with natural language. OptiFlow source, built off the same technology trusted by thousands of customers world-wide, upholds the robustness and sensitivity synonymous with SCIEX systems. 35% smaller footprint makes it the most compact triple quad in its class without compromising sensitivity or quantitative performance. 40% reduction in both energy consumption and laboratory cooling requirements helps to lower operational energy costs. Compatibility with any LC system, LIMS support, and 21 CFR Part 11 maintains compliance and operational confidence. “Analytical labs are being asked to deliver more insight with less time, space, and energy. With the novus V55 system, we have applied decades of innovation to ensure robustness and sensitivity, while enhancing performance and execution. This new generational instrument will help enable our customers to drive their business forward,” says Chris Lock, Vice President Global Research and Development at SCIEX. This 5th generation system builds on a proven legacy in nominal mass. In 1981, SCIEX launched the TAGA 6000, the first commercial triple quadrupole. Since then, the triple quadrupoles have evolved with the API III, then the API 4000, and then to the SCIEX Triple Quad series starting with SCIEX Triple Quad 5500 system. SCIEX also developed QTRAP technology which combined triple quad and linear ion trap technology for the first time. Learn more about the novus V55 system at https://sciex.com/products/mass-spectrometers/triple-quad-systems/novus-v55-system. ABOUT SCIEX SCIEX, a Danaher company and leader in life science analytical technologies, empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ? Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ? Advances in human wellness depend on the power of precise science.? For more information, visit sciex.com. ? Connect with us on LinkedIn, Facebook, and Instagram.? ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com. The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks). © 2026 DH Tech. Dev. Pte. Ltd. MKT-38491-A. View source version on businesswire.com: https://www.businesswire.com/news/home/20260601916060/en/ Lulu VanZandt
Senior Manager, Brand, Public Relations and Social Media

Danaher to Present at Bank of America Securities Healthcare ConferenceMay 6, 2026 4:15 PM
PR Newswire (US) WASHINGTON, May 6, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 13, 2026 at 11:20 a.m. PT. The event will be simultaneously webcast on www.danaher.com.ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com. View original content:https://www.prnewswire.com/news-releases/danaher-to-present-at-bank-of-america-securities-healthcare-conference-302764538.htmlSOURCE Danaher Corporation Original: Danaher to Present at Bank of America Securities Healthcare Conference

Danaher Announces Quarterly DividendMay 5, 2026 4:30 PM
PR Newswire (US) WASHINGTON, May 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 31, 2026 to holders of record on June 26, 2026.ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com. View original content:https://www.prnewswire.com/news-releases/danaher-announces-quarterly-dividend-302763206.htmlSOURCE Danaher Corporation Original: Danaher Announces Quarterly Dividend

Why Medtech Giants Are Quietly Paying Up for AI DiagnosticsApril 29, 2026 10:30 AM
PR Newswire (Canada)

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, April 29, 2026 /CNW/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical imaging market is on track to hit $2.20 billion in 2026, with a 34.8% growth rate baked in through 2033[1]. Q1 2026 healthcare M&A activity tells the same story: capital is rotating into AI-enabled platforms that already carry regulatory clearance, recurring revenue, and real clinical data behind them[2]. That description fits a short list of names worth knowing right now: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Medtronic (NYSE: MDT), Danaher (NYSE: DHR), Profound Medical (NASDAQ: PROF), and DexCom (NASDAQ: DXCM).







Hospitals are voting with their wallets too. A fresh C-suite survey shows 57% now rank AI clinical solutions as their top technology priority for 2026 to 2027, up from just 19% in 2023[3]. The FDA has made it clear that real-world clinical evidence is now central to clearing AI software, which is exactly why institutional buyers are paying a clinical validation premium for platforms that already have multi-site data behind them[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just picked up a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform, VMS+™ 4.0. The Edison Awards are widely considered one of the most prestigious innovation prizes in the world, often called "the Oscars of Innovation," and past Gold winners include Abbott, Medtronic, and Boston Scientific. For a small-cap medtech company out of Toronto, that is serious company to keep.The technology behind the award takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to a cardiac MRI, but without the million-dollar machine or the months-long wait list. VMS+™ 4.0 is already deployed in hospitals across the United States, Canada, the United Kingdom, and Europe, which is a key reason the Edison judges took notice. Their evaluation process places heavy weight on technologies that have moved past the pilot stage and into real clinical use.That momentum is showing up in VentriPoint's commercial pipeline. The company recently announced a collaboration with the Health Division of the Montecristo Group to roll out VMS+™ across Costa Rica's public and private hospital networks. The Montecristo Group's Hospital Metropolitano also has an existing relationship with Sanford Health, one of the largest healthcare systems in the United States. VentriPoint also recently partnered with First Light Health, an Indigenous-owned medical services company, to bring cardiac diagnostics to Indigenous and remote communities across Canada through a hub-and-spoke model. That program builds on an earlier partnership with the Nisga'a Valley Health Authority in northern BC. South of the border, the company signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California."Being awarded Gold affirms that VMS™ 4.0 has reached that threshold, and reinforces our belief that our platform has significant room to grow as adoption accelerates and new applications emerge," said Hugh MacNaught, CEO of VentriPoint.VentriPoint holds regulatory approvals in the United States, Canada, and Europe. Its VMS+™ platform is vendor-agnostic, meaning it works with ultrasound equipment from any manufacturer, and is built on more than a decade of proprietary Knowledge Based Reconstruction technology. The core value proposition is MRI-grade cardiac imaging at a fraction of the cost, deployable anywhere a standard ultrasound machine already sits. With a growing global footprint, a validated technology platform, and independent recognition from one of the world's top innovation bodies, VentriPoint is positioning itself as a name to watch in precision health.CONTINUED… Read this and more news for VentriPoint Diagnostics at:  https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointOther industry developments and happenings in the market include:Medtronic (NYSE: MDT) completed its acquisition of CathWorks, a privately held medical device company focused on coronary artery disease diagnosis and treatment, for $585 million with potential additional earn-out payments. The deal follows a 2022 co-promotion agreement and brings the CathWorks FFRangio System, an AI-powered, drug-free, wire-free coronary assessment platform, into Medtronic's interventional cardiology portfolio."The acquisition of CathWorks significantly enhances Medtronic's interventional cardiology portfolio with an innovative system that empowers physicians with data-driven insights for the diagnosis and treatment of coronary artery disease," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, part of the Cardiovascular Portfolio at Medtronic. "Through our global footprint, welcoming CathWorks to Medtronic will expand access to the transformative FFRangio technology for our customers and their patients worldwide."The FFRangio System recently demonstrated non-inferiority to wire-based physiology in the ALL-RISE randomized control trial, which enrolled more than 1,900 patients across 59 sites globally. The acquisition is expected to be immaterial to Medtronic's fiscal year 2027 earnings and neutral to accretive thereafter, continuing the company's strategy of targeted tuck-in acquisitions to strengthen its core franchises.Danaher (NYSE: DHR) reported first quarter 2026 results showing revenues of $6.0 billion, up 3.5% year-over-year, with non-GAAP adjusted diluted EPS growing 9.5% to $2.06. Operating cash flow reached $1.3 billion, supported by strength in Bioprocessing and better-than-expected Life Sciences performance."Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth," said Rainer M. Blair, President and CEO of Danaher. "On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid."Danaher raised its full year 2026 adjusted diluted EPS guidance to $8.35 to $8.55, up from prior guidance of $8.35 to $8.50, and expects full year core revenue growth of 3% to 6%. The company also announced its intention to acquire Masimo Corporation, a provider of pulse oximetry and patient monitoring solutions, citing opportunities to enhance performance through the Danaher Business System and its global scale.Profound Medical (NASDAQ: PROF) is highlighting its TULSA-PRO system across seven presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto, April 11-15. The commercial-stage medical device company's AI-powered, MRI-guided TULSA Procedure treats prostate cancer and benign prostatic hyperplasia without incisions, eliminating procedural blood loss and overnight hospital stays while minimizing side effects such as urinary incontinence and erectile dysfunction."Our significant presence at SIR 2026 comes at an opportune time as leading iMRI procedures, including MRI-guided biopsy and TULSA, are poised to transform how unmet medical needs across the prostate disease spectrum are being addressed," said Arun Menawat, CEO and Chairman of Profound Medical. "Awareness and acceptance of the TULSA Procedure's strong clinical profile, as well as its potential to become the next mainstream treatment modality for most men with prostate disease, is growing."Presentations will feature data from the Level 1 post-market CAPTAIN randomized controlled trial comparing TULSA against robotic prostatectomy for intermediate-risk prostate cancer. Profound Medical also commercializes Sonalleve, an MRI-guided therapy addressing bone metastases pain palliation, uterine fibroids, and adenomyosis, with its technologies approved across major global markets including the United States, Europe, and Canada.DexCom (NASDAQ: DXCM) is showcasing new clinical evidence at the 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, reinforcing the role of continuous glucose monitoring across all diabetes types. A multi-center primary care registry study showed that after one year of Dexcom G7 use, people with Type 2 diabetes not on insulin therapy saw significant improvements in A1C and weight management, while claims data linked Dexcom CGM initiation to meaningful reductions in DKA-related hospitalizations and emergency room visits in both children and adults with Type 1 diabetes."There is no better global stage than ATTD to showcase how we're shaping the future of glucose biosensing around the world," said Jake Leach, president and chief executive officer at DexCom. "The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin."Beyond the clinical data, DexCom is presenting its near- and long-term product roadmap, including upcoming features for Dexcom G7, Dexcom G7 15 Day, and Stelo, its health and wellness offering. The company recently launched Dexcom G7 15 Day in the U.S. and continues expanding its Dexcom Academy HCP education platform across Europe and the Middle East.Further Reading: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:
USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.coherentmarketinsights.com/industry-reports/ai-in-medical-imaging-market https://www.sikich.com/insight/q1-2026-healthcare-ma-market-update/ https://hitconsultant.net/2026/03/24/sage-growth-partners-health-it-purchasing-forecast-2026-2027-ai-roi/ https://www.fda.gov/news-events/fda-voices/real-world-evidence-advancing-regulatory-decision-making-medical-devices Logo - https://mma.prnewswire.com/media/2838876/5919929/USA_News_Group_Logo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/why-medtech-giants-are-quietly-paying-up-for-ai-diagnostics-302757277.html

Original: Why Medtech Giants Are Quietly Paying Up for AI Diagnostics

Danaher Announces Pricing of Euro-Denominated Senior Notes OfferingApril 22, 2026 7:15 PM
PR Newswire (US)

WASHINGTON, April 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that it has priced an offering of the following euro-denominated senior notes (the "Offering"):
€500,000,000 principal amount of floating rate senior notes due 2028 at an offering price of 100.000% of the principal amount;€750,000,000 principal amount of 3.250% senior notes due 2030 at an offering price of 99.934% of the principal amount;€750,000,000 principal amount of 3.625% senior notes due 2034 at an offering price of 99.918% of the principal amount; and€1,000,000,000 principal amount of 4.000% senior notes due 2038 at an offering price of 99.953% of the principal amount (collectively, the "senior notes").Danaher estimates that the net proceeds from the sale of the senior notes will be approximately €2.98 billion, after deducting the underwriting discounts and estimated offering expenses payable by Danaher. Danaher intends to use the net proceeds from the sale of the senior notes to pay a portion of the cash consideration payable for, and certain costs associated with, its acquisition of Masimo Corporation. Danaher may also use a portion of the net proceeds from the sale of the senior notes for general corporate purposes, which may include, without limitation and in Danaher's sole discretion, refinancing of outstanding indebtedness, working capital, capital expenditures and satisfaction of other obligations. The Offering is expected to close on April 29, 2026, subject to the satisfaction of customary closing conditions.The Offering is being made pursuant to an effective shelf registration statement on Form S-3ASR (File No. 333-278426) filed by Danaher with the U.S. Securities and Exchange Commission on April 1, 2024, and only by means of a prospectus and prospectus supplement. A preliminary prospectus supplement and an issuer free writing prospectus have been filed, and a prospectus supplement relating to the Offering will be filed, with the SEC, to which this communication relates. Prospective investors should read the issuer free writing prospectus, preliminary prospectus supplement and accompanying prospectus forming a part of that registration statement and the other documents that Danaher has filed with the SEC for more complete information about Danaher and the Offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. A copy of the prospectus and prospectus supplement relating to the securities can also be obtained by calling Citigroup Global Markets Limited at +1-800-831-9146; Merrill Lynch International at +1-800-294-1322; Barclays Bank PLC at +1-888-603-5847; Deutsche Bank AG, London Branch at +1-800-503-4611; and Goldman Sachs & Co. LLC at +1-866-471-2526.This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, the senior notes or any other securities, nor shall there be any offer, solicitation or sale of any security mentioned in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The senior notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("EEA"). For these purposes, a retail investor means a person who is one (or more) of the following: (i) a "retail client" as defined in point (11) of Article 4(1) of Directive (EU) 2014/65 (as amended, "MiFID II") or (ii) a customer within the meaning of Directive (EU) 2016/97, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or selling the senior notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the senior notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.The senior notes are not intended to be offered, sold, distributed or otherwise made available to and should not be offered, sold, distributed or otherwise made available to any retail investor in the UK. For these purposes, a retail investor means a person who is not a professional client as defined in Article 2(1)(8) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. Consequently no disclosure document required by the FCA Product Disclosure Sourcebook ("DISC") for offering, selling, or distributing the senior notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering, selling or distributing the senior notes or otherwise making them available to any retail investor in the UK may be unlawful under DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024.This communication is being distributed only to, and is directed at persons who (i) persons who are outside the UK, (ii) persons who have professional experience in matters relating to investments and are investment professionals as defined within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (iii) high net worth bodies corporate and any other person falling within Article 49(2)(a) to (d) of the Order, or (iv) persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This announcement is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 60,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow.FORWARD-LOOKING STATEMENTSStatements in this release that are not strictly historical, including the statements regarding the timing and completion of the Offering, the anticipated use of proceeds therefrom and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be "forward-looking statements" within the meaning of the federal securities laws. There are a number of important factors that could cause actual events, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Danaher's SEC filings, including Danaher's 2025 Annual Report on Form 10-K and Danaher's Quarterly Report on Form 10-Q for the first quarter of 2026. These forward-looking statements speak only as of the date of this release and, except to the extent required by applicable law, Danaher does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.



View original content:https://www.prnewswire.com/news-releases/danaher-announces-pricing-of-euro-denominated-senior-notes-offering-302750942.htmlSOURCE Danaher Corporation

Original: Danaher Announces Pricing of Euro-Denominated Senior Notes Offering

Danaher Reports First Quarter 2026 ResultsApril 21, 2026 6:00 AM
PR Newswire (US)

WASHINGTON, April 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.Key First Quarter 2026 ResultsNet earnings were $1.0 billion, or $1.45 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 9.5% to $2.06.Revenues increased 3.5% year-over-year to $6.0 billion and non-GAAP core revenue increased 0.5% year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Strong Q1 earnings performance enabling increased full year 2026 adjusted diluted net earnings per common share guidance.Rainer M. Blair, President and Chief Executive Officer, stated, "Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth.  On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid."Mr. Blair continued, "We were also pleased to announce our intention to acquire Masimo Corporation, a leading provider of mission-critical pulse oximetry and patient monitoring solutions in acute care settings.  We believe there are clear opportunities to enhance Masimo's performance through DBS and our global scale.  Looking ahead, the strength of our balance sheet and free cash flow generation provides additional capacity for value-creating capital deployment."Second Quarter and Full Year 2026 OutlookDanaher Corporation (the "Company") does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $1.7 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which for the second quarter and full year 2026 is estimated to increase sales by 0.5% in both periods, assuming the currency exchange rates in effect as of March 27, 2026) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control.  The impact of these additional elements could be material to our results computed in accordance with GAAP.For the second quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the low-single digit percent range year-over-year.For full year 2026, the Company continues to expect that non-GAAP core revenue will increase in the 3% to 6% range year-over-year.  The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.35 to $8.55 versus previous guidance of $8.35 to $8.50.Conference Call and Webcast InformationDanaher will discuss its first quarter results and financial guidance for the second quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET.  The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations."  A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.The conference call can be accessed by dialing 800-267-6316, within the U.S. or +1 203-518-9783 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ126).  A replay of the conference call will be available shortly after the conclusion of the call and until May 5, 2026.  You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.  Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies.  Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.  Explore more at www.danaher.com.NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALSIn addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures.  Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).FORWARD-LOOKING STATEMENTS AND OTHER INFORMATIONStatements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the second quarter and full year 2026, the Company's anticipated acquisition of Masimo Corporation (which remains subject to customary closing conditions, including regulatory approval) and anticipated opportunities with respect thereto, anticipated free cash flow generation, the Company's prospects for capital deployment and driving long-term shareholder value, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including any debt we incur to finance the pending acquisition of Masimo Corporation)  on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our pending acquisition of Masimo), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and  military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2026.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.DANAHER CORPORATION AND SUBSIDIARIESCONSOLIDATED CONDENSED STATEMENTS OF EARNINGS ($ and shares in millions, except per share amounts)(unaudited)

Three-Month Period Ended
March 27, 2026
March 28, 2025Sales$            5,951
$            5,741Cost of sales(2,360)
(2,230)Gross profit3,591
3,511Operating costs:


Selling, general and administrative expenses(1,860)
(1,858)Research and development expenses(387)
(379)Operating profit1,344
1,274Nonoperating income (expense):


Other income (expense), net(73)
(79)Interest expense(63)
(72)Interest income27
6Earnings before income taxes1,235
1,129Income taxes(206)
(175)Net earnings $            1,029
$              954Net earnings per common share:


Basic$             1.45
$             1.33Diluted$             1.45
$             1.32Average common stock and common equivalent shares outstanding:


Basic707.9
716.3Diluted711.2
720.8This information is presented for reference only.  A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com).
Diluted Net Earnings Per Common Share and Adjusted Diluted Net Earnings Per Common Share 

Three-Month Period Ended
March 27, 2026
March 28, 2025Diluted Net Earnings Per Common Share (GAAP)$             1.45
$             1.32Amortization of acquisition-related intangible assets A0.61
0.57Fair value net (gains) losses on investments B0.11
0.12Acquisition-related items C0.02
—Impairments D—
0.02Gain on a product line disposition E—
(0.01)Tax effect of the above adjustments F(0.13)
(0.13)Discrete tax adjustments G—
(0.01)Adjusted Diluted Net Earnings Per Common Share (Non-GAAP)$             2.06
$             1.88Notes to Reconciliation of GAAP to Non-GAAP Financial MeasuresA Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):
Three-Month Period Ended
March 27, 2026
March 28, 2025Pretax$              434
$              410After-tax360
340B Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended
March 27, 2026
March 28, 2025Pretax$               77
$               90After-tax59
68C Transaction costs related to the anticipated acquisition of Masimo Corporation ("Masimo") in the three-month period ended March 27, 2026 ($17 million pretax as reported in this line item, $15 million after-tax).  The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.D Impairment charges related to a facility in the Biotechnology segment recorded in the three-month period ended March 28, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).E Gain on a product line disposition in the three-month period ended March 28, 2025 ($9 million pretax as reported in this line item, $7 million after-tax).F This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table.  In addition, the footnotes above indicate the after-tax amount of each individual adjustment item.  Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.G There were no net discrete tax adjustments and other tax-related adjustments for the three-month period ended March 27, 2026, as the release of reserves for uncertain tax positions due to the expiration of statutes of limitations was offset by charges related to changes in estimates associated with prior period uncertain tax positions.  Discrete tax adjustments and other tax-related adjustments for the three-month period ended March 28, 2025, include the impact of net discrete tax benefits of $10 million related primarily to changes in estimates of prior year tax filing positions, release of reserves for uncertain tax positions due to the expiration of statutes of limitations and excess tax benefits from stock-based compensation, net of charges related to changes in estimates associated with prior period uncertain tax positions.

Sales Growth (Decline) by Segment and Core Sales Growth (Decline) by Segment

% Change Three-Month Period Ended March 27, 2026 vs. Comparable 2025 Period


Segments
Total Company
Biotechnology
Life Sciences
DiagnosticsTotal sales growth (decline) (GAAP)3.5 %
11.5 %
3.5 %
(1.5) %Impact of:






Currency exchange rates (3.0) %
(4.5) %
(3.0) %
(2.5) %Core sales growth (decline) (non-GAAP)0.5 %
7.0 %
0.5 %
(4.0) %Forward-Looking Information

% Change Three-
Month Period
Ending June 26,
2026 vs.
Comparable 2025
Period
% Change Year
Ending December
31, 2026 vs.
Comparable 2025
PeriodCore sales growth (non-GAAP)


Biotechnology+Mid-single digit
~+6.0%Life Sciences+Up slightly
+Up slightlyDiagnosticsFlat
+Low-single digitTotal Company+Low-single digit
+3.0% - +6.0%




Three-Month
Period Ending June 26, 2026
Year Ending December 31, 2026Adjusted operating profit margin (non-GAAP)~26.5 %

Adjusted diluted net earnings per common share (non-GAAP)

$8.35 - $8.55Cepheid respiratory revenue ($ in billions)

~$1.6 - $1.7Impact of currency exchange rates on sales H~+0.5 %
~+0.5 %Corporate expense I ($ in millions)~$(90)
~$(360)Interest expense, net J ($ in millions)~$(40)
~$(140)Effective tax rate ~17.0 %
 ~17.0 %Average adjusted diluted shares (in millions)~712.0
~714.0H Impact of currency exchange rates on sales for the second quarter and full year 2026 assumes the currency exchange rates in effect as of March 27, 2026.I Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management's evaluation of reportable segment operating performance.J Interest expense, net is defined as interest expense net of interest income.  This line item is an assumption rather than a forecast.  The estimated interest expense, net is calculated assuming the currency exchange rates in effect as of March 27, 2026 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding, nor does it include an estimate for incremental net interest expense related to the financing for the anticipated acquisition of Masimo Corporation ("Masimo").Cash Flow and Free Cash Flow($ in millions)


Three-Month Period Ended
March 27, 2026
March 28, 2025Total Cash Flow:


Net cash provided by operating activities (GAAP)$            1,322
$            1,299Total cash used in investing activities (GAAP)$              (249)
$              (242)Total cash provided by (used in) financing activities (GAAP)$                 46
$           (1,255)



Free Cash Flow:


Net cash provided by operating activities (GAAP)$            1,322
$            1,299Less: payments for additions to property, plant & equipment (capital expenditures) (GAAP)(237)
(245)Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP)—
6Free cash flow (non-GAAP)$            1,085
$            1,060We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment ("capital expenditures") plus the proceeds from sales of plant, property and equipment ("capital disposals"). Statement Regarding Non-GAAP MeasuresEach of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.  Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors:with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers;with respect to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; andwith respect to free cash flow (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).Management uses the non-GAAP measures referenced above to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share, Adjusted Operating Profit and the FCF Measure in the Company's executive compensation program.The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:With respect to the profitability-related non-GAAP measures:Amortization of Intangible Assets:  We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate.  While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition.  Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies.  We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.Restructuring Charges:  We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System.  Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.Other Adjustments:  With respect to the other items excluded from the profitability-related non-GAAP measures, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. With respect to core sales, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements. 



View original content:https://www.prnewswire.com/news-releases/danaher-reports-first-quarter-2026-results-302747922.htmlSOURCE Danaher Corporation

Original: Danaher Reports First Quarter 2026 Results

Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 MinutesApril 13, 2026 3:01 AM
PR Newswire (US)

Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems through Fewer Unnecessary Admissions and Testing BREA, Calif., April 13, 2026 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and global leader in clinical diagnostics, today announced it has received CE 2797 mark under IVDR for the Access MeMed BV assay, enabling broad availability of a high-throughput host-response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes.







Validated for use across Beckman Coulter's installed base of DxI 9000 and Access 2 immunoassay analyzers, the Access MeMed BV assay enables fast, reliable infection differentiation while leveraging laboratories' existing infrastructure and workflows. Beckman Coulter partnered with MeMed, a leader in advanced host-response technologies, to bring the proven MeMed BV® test into core laboratory settings. The MeMed BV test has been shown to enhance clinical decision-making, support clinicians in curbing unnecessary antibiotic use, and advance antimicrobial-stewardship initiatives—results reinforced by strong clinical studies and real-world performance data.1-7Published MeMed economic data, together with incidence estimates for lower respiratory tract infections (LRTI) and community-acquired pneumonia (CAP), indicate that European healthcare systems shoulder significant avoidable costs each year.8-10 With Access MeMed BV now available on Beckman Coulter's extensive installed base across Europe, healthcare systems have a scalable, practical path to help potentially reduce up to €80 million in avoidable costs through reductions in unnecessary admissions and diagnostic testing."By delivering rapid, highly reliable bacterial and viral differentiation on routine immunoassay systems, we're empowering care teams with the timely insights they need to guide appropriate treatment decisions, while optimizing laboratory efficiency using existing workflows," said Melissa Naiman, Medical & Scientific Affairs at Beckman Coulter Diagnostics.""This collaboration with Beckman Coulter significantly accelerates our mission to make host-response testing available at scale," said Eran Eden, CEO & Co-founder, MeMed. "The MeMed BV test has repeatedly demonstrated its ability to improve clinical decision making, empower clinicians to reduce unnecessary antibiotic use, and support antimicrobial stewardship, backed by robust clinical and real-world evidence. Making the assay available on high-throughput laboratory analyzers allows healthcare systems to unlock those benefits for far more patients."Fast Insights Guides Confident Clinical DecisionsBacterial and viral infections frequently present with similar symptoms, making early differentiation challenging and sometimes leading to inappropriate patient management or unnecessary antibiotic use. Early distinction is critical because clinicians often must prescribe treatment before traditional diagnostic methods—which can take hours or days—to deliver definitive results. The Access MeMed BV assay provides actionable bacterial vs. viral insights in approximately 20 minutes, using Beckman Coulter immunoassay analyzers to generate rapid results at scale.Recent real-world studies across nearly 6,000 adult and pediatric patients found that clinicians face uncertainty about antibiotic prescribing in approximately 16–29% of cases.3-5 Following receipt of MeMed BV results, physicians reported that the test supported or changed clinical decision-making in approximately 82–87% of cases. In prior blinded multicenter validation studies, MeMed BV demonstrated up to 99% negative predictive value (NPV) as an aid in excluding bacterial infection.11-13Reducing Costs, Hospitalizations, and Unnecessary Antibiotic Use at ScaleChallenges in accurately identifying bacterial versus viral infections early can drive downstream healthcare costs, unnecessary admissions, and repeat testing. Independent health-economic modeling highlights the potential value of incorporating MeMed BV into routine care.10For every 1,000 patients evaluated for suspected community-acquired pneumonia (CAP), incorporating MeMed BV into clinical decision-making- generated substantial efficiencies. In adults, the model showed £134,018 in total cost savings, while pediatric care realized £105,750 in avoided costs. These financial gains were driven by more targeted antibiotic use, reduced hospitalizations, and fewer diagnostic procedures—resulting in streamlined care pathways and lower resource consumption.10 About Access MeMed BV Assay The Access MeMed BV Assay is a diagnostic test indicated for use in patients presenting to a medical center and inpatients with suspected acute bacterial or viral infection. The test integrates measurements of three key host-immune proteins (TRAIL, IP-10, and CRP) into a score indicating the likelihood of bacterial or viral infections.About Beckman Coulter. Inc. A global leader in advanced diagnostics, Beckman Coulter Diagnostics has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 90 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Beckman Coulter is part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies. Headquartered in Brea, Calif., it has more than 11,000 global team members.Follow and connect with Beckman Coulter via LinkedIn, Twitter, and Facebook.ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.© 2026 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. MeMed BV is a registered trademark for MeMed. 2026-152951 Singer et al. 2025. Effect of host-protein test (TRAIL/IP-10/CRP) on antibiotic prescription and emergency department or urgent care center return visits: the JUNO pilot randomized controlled trial. Academic Emergency Medicine Journal.2 LoVerde et al. 2025. Real-world study assessing sensitivity and clinical utility of a host-protein test in adult emergency departments patients with blood culture ordered. JACEP Open.3 Kalmovich B. et al. 2023. Impact on patient management of a novel host response test for distinguishing bacterial from viral infections: real world evidence from the urgent care setting. Biomedicines.4 Kalmovich B. et al. 2025. Implementation of a rapid host-protein diagnostic test for distinguishing bacterial and viral infections in adults presenting to urgent care centers: a pragmatic cohort study. BMC Medicine.5 Kalmovich B. et al. 2025. Use of a host-protein test for pediatric acute infections at urgent care centers. Pediatrics.6 Diamantopoulou P. et al. 2026. Real-world utility of the host-response MeMed BV test in a pediatric emergency department: A non-randomized study with optimized antimicrobial and diagnostic stewardship. Children.7 van Houten C.B. et al. 2016. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. Lancet Infectious Diseases.8 Bender R. et al. 2024. Global, Regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the global burden of disease study 2021.9 Reyes L.F. et al. 2025. Community-acquired pneumonia. The Lancet.10 Gregg E. et al. 2025. Host-response testing with MeMed BV in community-acquired pneumonia: an economic evaluation from the UK NHS perspective. JAC-Antimicrobial Resistance.11 Bachur R.G. et al. 2024. A rapid host-protein test for differentiating bacterial from viral infection: Apollo diagnostic accuracy study. JACEP Open.12 Allen C. et al. 2025. Development of a reference standard to assign bacterial versus viral infection etiology using an all-inclusive methodology for comparison of novel diagnostic tool performance. Clinical Infectious Diseases.13 Papan C. et al. 2022. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: a prospective, multicentre cohort study. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-diagnostics-earns-ce-mark-for-new-assay-delivering-bacterial-vs-viral-infection-results-in-approximately-20-minutes-302740015.htmlSOURCE Beckman Coulter Diagnostics

Original: Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes

AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesApril 9, 2026 9:00 AM
InvestorsHub NewsWireAI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost AdvantagesAINewsWire Editorial Coverage: As regulatory demands intensify and production environments become more complex, pharmaceutical manufacturers are shifting beyond traditional quality assurance systems toward a new operational model: integrating artificial intelligence directly into manufacturing workflows as a continuous compliance layer. Rather than depending on retrospective audits and manual checks, AI-driven technologies are now capable of monitoring, validating and optimizing production processes in real time to ensure alignment with evolving Good Manufacturing Practice ("GMP") requirements. This transformation is becoming increasingly visible across the sector and aligns with companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile), which operate at the intersection of biotechnology and advanced digital systems, reflecting a broader transition toward intelligent, automated compliance infrastructures. Through its focus on AI, Oncotelic sits alongside other innovation-driven organizations including Rockwell Automation Inc. (NYSE: ROK), Emerson Electric Co. (NYSE: EMR), Thermo Fisher Scientific Inc. (NYSE: TMO) and Danaher Corp. (NYSE: DHR), all of which are contributing to this evolving technological landscape.Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.Regulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing.Current obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.A more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Click here to view the custom infographic of the Oncotelic Therapeutics editorial.Embedded Intelligence Enables Continuous ComplianceHistorically, pharmaceutical manufacturing relied heavily on batch-based testing and manual recordkeeping to verify compliance. While these methods were sufficient in earlier production models, they often introduce delays and create opportunities for human error. Increasingly, manufacturers are adopting AI-powered continuous monitoring systems that evaluate compliance dynamically throughout the production process rather than after completion.This shift supports initiatives from the U.S. Food and Drug Administration ("FDA"), which has encouraged the adoption of advanced manufacturing technologies and continuous production models. Programs such as the FDA's Emerging Technology Program and Advanced Manufacturing Technologies initiative promote the use of innovative systems designed to enhance reliability, improve product quality and minimize the risk of manufacturing failures or supply disruptions. These efforts highlight a transition from reactive oversight to proactive compliance strategies.AI technologies facilitate this transformation by regularly evaluating streams of production data, including variables such as temperature, pressure and material uniformity, to identify anomalies as they occur. Rather than detecting issues during post-production reviews, these systems enable immediate intervention, helping maintain product integrity. This ability supports real-time release testing, a model in which products are evaluated and approved based on live process data instead of delayed laboratory testing.As this approach gains adoption, companies such as Oncotelic Therapeutics are part of a broader ecosystem that increasingly views embedded intelligence as a core component of compliance. Their alignment with AI-enabled platforms reflects a growing understanding that compliance is no longer a discrete checkpoint, but an integrated function operating continuously across the manufacturing lifecycle.Heightened Regulation Accelerates Automation AdoptionRegulatory bodies around the world are placing increasing emphasis on data integrity, traceability and minimizing human error. The European Medicines Agency has released detailed guidance on computerized systems and data management, stressing the importance of secure, attributable and contemporaneous records. Likewise, FDA expectations reinforce following ALCOA+ principles, which ensure that data is attributable, legible, contemporaneous, original and accurate.These rising standards are hastening the move toward automation. Manual processes, which have long been standard across pharmaceutical manufacturing, are now seen as potential sources of variability and documentation risk. According to the International Society for Pharmaceutical Engineering, digital transformation initiatives are becoming essential to improving compliance outcomes and reducing operational risk in modern pharmaceutical systems.AI-enhanced automation provides a solution by standardizing workflows and ensuring consistent data capture. These systems automatically generate audit-ready documentation, reducing reliance on human input while improving transparency and accuracy. In sterile manufacturing environments, where contamination risks must be minimized, automation also reduces human involvement, thereby reinforcing compliance outcomes.Within this regulatory environment, Oncotelic Therapeutics represents a wider strategic alignment with innovation driven by compliance requirements. As pharmaceutical companies increasingly prioritize automation and data integrity, organizations leveraging AI-enabled platforms are better positioned to meet evolving regulatory expectations.Pharma 4.0 Drives Intelligent Production EcosystemsThe idea of Pharma 4.0 characterizes a significant evolution in pharmaceutical development and manufacturing. Sparked by Industry 4.0, this model integrates digital technologies such as artificial intelligence, robotics and advanced analytics into interconnected production systems. Research indicates that these technologies are transforming biopharma operations by increasing productivity, improving product quality and supporting more agile, data-driven decision-making across the value chain.In such environments, manufacturing systems are fully connected, enabling data to move between equipment, quality systems and supply chain processes. AI-driven analytics use this data to optimize performance, anticipate maintenance needs and ensure compliance. This integration enhances traceability, enabling manufacturers to monitor every stage of production with greater precision.Large pharmaceutical companies are now employing these capabilities. Pfizer Inc. has implemented digital manufacturing programs that leverage AI and data-driven systems to improve efficiency and operational performance. Johnson & Johnson has invested in AI-powered platforms to enhance decision-making and streamline development processes, while Novartis AG is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments. These initiatives demonstrate a broader industry commitment to adopting intelligent manufacturing as a pathway to improved compliance and operational efficiency.Within this context, Oncotelic Therapeutics represents a growing class of entities operating at the intersection of biotechnology and digital innovation. As Pharma 4.0 adoption increases, organizations supporting AI-enabled systems are increasingly positioned to participate in scalable, data-driven manufacturing ecosystems.Efficiency Gains Reduce Cost, RiskThe process of bringing a new pharmaceutical product to market remains both time-consuming and expensive, often requiring more than a decade of development and substantial financial investment. A substantial part of these expenses are caused by high failure rates, increasing process complexity and inefficiencies across development and manufacturing stages. These obstacles underscore the demand for increasingly dependable data-driven systems, with AI-enabled automation paving the way for reduced variability, enhanced consistency and decreased costly disruptions.Deloitte has noted that digital transformation in life sciences manufacturing can boost operational efficiency by streamlining processes, increasing productivity and reducing errors. AI systems can evaluate both real-time and historical data to anticipate possible problems, allowing manufacturers to intervene before issues escalate.Continuous manufacturing, frequently supported by AI and advanced process control technologies, further improves efficiency by reducing reliance on large-batch production. Instead, it enables continuous processing with real-time monitoring, lowering inventory requirements and accelerating time-to-market. The FDA has actively supported this approach, recognizing its ability to improve product quality, reduce costs and provide a more flexible alternative to traditional batch manufacturing.The combination of reduced risk and improved efficiency creates a compelling value proposition for companies operating at the intersection of AI and biotechnology. In this environment, organizations such as Oncotelic Therapeutics reflect the growing importance of platforms capable of supporting intelligent automation and compliance as the industry seeks to manage costs more effectively.AI, Robotics Reshape Biotech InfrastructureA more significant change is underway as artificial intelligence, robotics and biotechnology come together to reshape pharmaceutical infrastructure. Modern manufacturing facilities increasingly rely on robotic systems to automate complex processes such as aseptic filling, material handling and inspection, decreasing the need for human intervention while improving precision and efficiency. In addition, AI-driven systems monitor operations in real time, analyzing data to detect irregularities and optimize performance, supporting continuous compliance.This meeting of technology is especially significant in sterile manufacturing environments, where minimizing human involvement is essential to reducing contamination risk. Robotics provide precision and consistency, while AI systems continuously monitor environmental conditions and process variables. These technologies come together to make integrated systems that sustain both compliance and operational quality.Market data highlights the reach of this transformation. The global pharmaceutical manufacturing sector, already valued in the hundreds of billions of dollars, is expected to reach $1 trillion in the coming years. Investment is increasingly directed toward automation, digital infrastructure and AI-enabled production systems designed to improve efficiency and regulatory compliance. This trend indicates a broader reallocation of capital toward technologies that enhance scalability, precision and operational control.As this movement continues to climb upward, companies aligned with AI-driven platforms may benefit from sustained growth and improved margins. Positioned within this evolving landscape, Oncotelic Therapeutics represents the type of organization that could participate in this transformation, where intelligent automation and integrated compliance redefine pharmaceutical manufacturing.AI and Robotics Drive Next Phase of TransformationArtificial intelligence and robotics are rapidly reshaping industrial operations, enabling companies to improve efficiency, reduce manual intervention and unlock new levels of productivity. Across manufacturing, infrastructure and life sciences, organizations are increasingly deploying intelligent automation systems that combine real-time data, machine learning and advanced robotics to streamline workflows and support decision-making.Rockwell Automation Inc. (NYSE: ROK) announced a major step in real-time intelligence for industrial teams. The company introduced its integration of NVIDIA Nemotron Nano, a purpose-built small language model ("SLM") optimized for FactoryTalk(R) Design Studio(TM) and other Rockwell product workflows. In collaboration with NVIDIA, Rockwell is leveraging the open-source Nemotron-Nano-9B-v2 model and NVIDIA NeMo to deliver an edge-based generative AI capability designed specifically for industrial environments.Emerson Electric Co. (NYSE: EMR) has introduced a new AI-powered environment to enhance upstream lifecycle decision making. Emerson's AspenTech Subsurface Intelligence(TM) ("ASI") is an open, cloud-native agentic environment that incorporates AI to transform the user experience and accelerate subsurface-related decision making while leveraging existing investments in legacy applications. ASI fulfills a critical industry need to work in an agile, multidisciplinary manner, optimize production and improve access to information trapped throughout various parts of the organization.Thermo Fisher Scientific Inc. (NYSE: TMO) integrates AI and robotics into laboratory and semiconductor environments with its Thermo Scientific Vulcan(TM) Automated Lab. The platform is designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system enhances productivity, increases yield and reduces operating costs for semiconductor manufacturers.Danaher Corp. (NYSE: DHR) announced a collaboration designed to enhance life science lab connectivity by integrating automated imaging and detection systems into research workflows. Molecular Devices, LLC., a leading provider of high-performance life science solutions and an operating company of Danaher is partnering with Automata, a London-based lab automation company developing fully integrated, AI-ready platforms for life science researchers. As labs face mounting pressure to boost throughput and data quality while managing limited hands-on resources, new integrations between Molecular Devices' imaging and detection systems and Automata's LINQ platform will provide a scalable, interoperable foundation for fully connected research workflows.These developments reflect a broader transformation across industrial and scientific sectors, where AI and robotics are becoming foundational technologies rather than experimental tools. As companies continue to integrate intelligent systems into core operations, these advancements highlight the growing importance of automation in driving efficiency, scalability and long-term competitiveness across the global economy.For more information, visit Oncotelic Therapeutics Inc.
Original: AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages

Danaher Schedules First Quarter 2026 Earnings Conference CallMarch 20, 2026 4:15 PM
PR Newswire (US)

WASHINGTON, March 20, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2026 on Tuesday, April 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You can access the conference call by dialing 800-267-6316, within the U.S. or +1 203-518-9783 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ126). A replay of the conference call will be available shortly after the conclusion of the call until May 5, 2026. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."Danaher's earnings press release, the webcast slides and other related materials will be posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings" beginning at 6:00 a.m. ET on the date of the earnings call and will remain available following the call.ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 60,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.



View original content:https://www.prnewswire.com/news-releases/danaher-schedules-first-quarter-2026-earnings-conference-call-302719984.htmlSOURCE Danaher Corporation

Original: Danaher Schedules First Quarter 2026 Earnings Conference Call

Danaher Announces Quarterly DividendFebruary 24, 2026 4:30 PM
PR Newswire (US)

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026.ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 60,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.



View original content:https://www.prnewswire.com/news-releases/danaher-announces-quarterly-dividend-302696224.htmlSOURCE Danaher Corporation

Original: Danaher Announces Quarterly Dividend

Masimo jumps over 30% on report of potential $10 billion Danaher takeoverFebruary 17, 2026 9:43 AM
IH Market News
Masimo Corporation (NASDAQ:MASI) rallied more than 32% in U.S. premarket trading Tuesday following a report from the Financial Times that Danaher Corporation (NYSE:DHR) is nearing a deal worth almost $10 billion to acquire the medical technology group.According to the newspaper, which cited sources familiar with the discussions, an agreement for the California-based company could be unveiled as soon as Tuesday.Such a transaction would represent a premium to Masimo’s market capitalization of nearly $7 billion at Friday’s close.Masimo is known for producing medical monitoring technologies, including pulse oximeters, and has previously accused Apple Inc. (NASDAQ:AAPL) of violating its intellectual property rights.Danaher has built a reputation for sustained acquisition activity over the past 25 years, including its landmark $21.4 billion purchase of Cytiva in 2020.Masimo Corporation stock priceDanaher stock price

Original: Masimo jumps over 30% on report of potential $10 billion Danaher takeover

Danaher To Acquire Masimo CorporationFebruary 17, 2026 8:00 AM
PR Newswire (US)

WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2027 estimated EBITDA including the full benefit of expected annual synergies1.Rainer M. Blair, President and Chief Executive Officer, Danaher, said: "We are excited to welcome the Masimo team to Danaher. We've followed this innovative company for many years and see it as an exceptional strategic fit for Danaher. Masimo is a leader in pulse oximetry and other patient monitoring solutions, which combined with its trusted brand and differentiated technology, will greatly strengthen our diagnostics franchise. With the Danaher Business System and our global scale, we see opportunities to expand Masimo's reach and continue improving outcomes for patients, particularly those in acute care settings."Julie Sawyer Montgomery, Executive Vice President for Diagnostics, Danaher, said: "Masimo's advanced sensor technology and AI-enabled monitoring bring powerful new capabilities to our diagnostics portfolio. Integrating these strengths into Danaher will create meaningful opportunities to innovate for clinicians and improve decision making in critical settings."Upon completion of the transaction, Masimo will be a standalone operating company within Danaher's Diagnostics segment along with Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics. Masimo is expected to be accretive to adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year and approximately $0.70 in the fifth full year following completion of the acquisition. Masimo is expected to deliver high-single digit core revenue growth over the long-term, accelerating Danaher's Diagnostics segment core revenue growth profile.Under Danaher's ownership, Masimo is expected to generate EBITDA of more than $530 million in 2027. Additionally, Danaher expects to realize more than $125 million of annual cost synergies and more than $50 million of annual revenue synergies by the fifth full year following completion of the acquisition.The transaction is anticipated to close in the second half of 2026 and is subject to customary conditions, including receipt of applicable regulatory clearances and Masimo shareholder approval. Danaher expects to fund the acquisition using cash on hand and proceeds from debt financing.Citi acted as financial advisor to Danaher. Kirkland & Ellis LLP served as legal advisor to Danaher in connection with the Transaction.Core revenue growth, adjusted diluted net earnings per common share and EBITDA are non-GAAP measures; please see "Non-GAAP Measures" below for additional information. 1 2027 estimated EBITDA including the full benefit of expected annual synergies refers to 2027 estimated EBITDA adjusted to include the full benefit of annual synergies expected to be achieved by the fifth full year following acquisition.A note containing additional financial and other information relating to Danaher's anticipated acquisition of Masimo has been posted to the "Investors" section of Danaher's public website (www.danaher.com ).ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 60,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.NON-GAAP MEASURES
This communication contains the non-GAAP financial measures of core revenue growth, adjusted diluted net earnings per common share and EBITDA. Core revenue growth excludes the impact of currency translation and the effect of acquisitions and divested product lines. Adjusted diluted net earnings per common share in this calculation excludes amortization of intangible assets, purchase accounting charges and transaction expenses attributable to the acquisition. EBITDA is defined as earnings before interest, taxes, depreciation and amortization. The items excluded from these non-GAAP measures have been excluded because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to the business' commercial performance during the particular period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.Each of these non-GAAP measures should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing the results of Danaher and/or the acquired business, as applicable, that, when reconciled to the corresponding GAAP measure, help our investors understand the impact of the acquisition to Danaher's profitability, growth and future prospects. Management uses these non-GAAP measures to measure Danaher's operating and financial performance and to assess anticipated operating and financial performance of the acquired business.Danaher does not reconcile these forecasted non-GAAP measures to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP. IMPORTANT INFORMATION AND WHERE TO FIND IT
In connection with the proposed transaction (the "Transaction"), Masimo and Danaher intend to file relevant materials with the SEC, including Masimo's proxy statement in preliminary and definitive form. Masimo will mail the definitive proxy statement and a proxy card to its stockholders in advance of the stockholders meeting in connection with the Transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Masimo with the SEC. INVESTORS AND STOCKHOLDERS OF MASIMO ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED BY EACH OF DANAHER AND MASIMO WITH THE SEC IN CONNECTION WITH THE TRANSACTION OR INCORPORATED BY REFERENCE THEREIN, INCLUDING MASIMO'S PROXY STATEMENT (WHEN THEY ARE AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT MASIMO, DANAHER, AND THE TRANSACTION AND RELATED MATTERS. Investors and stockholders are or will be able to obtain these documents (when they are available) free of charge from the SEC's website at www.sec.gov. Danaher and Masimo make available free of charge at the Danaher website at https://investors.danaher.com/sec-filings and Masimo's website at https://investor.masimo.com/overview/, respectively, copies of documents they file with, or furnish to, the SEC. The contents of the websites referenced above will not be deemed to be incorporated by reference into the proxy statement.PARTICIPANTS IN THE SOLICITATION
This communication does not constitute a solicitation of a proxy. Masimo, Danaher and their respective directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be "participants" in the solicitation of proxies from stockholders of Masimo in favor of the Transaction. Information about Masimo's directors and executive officers is set forth in Masimo's Proxy Statement on Schedule 14A for its 2025 Annual Meeting of Stockholders, which was filed with the SEC on March 26, 2025, including under the headings entitled "Our Board of Directors", "Our Executive Officers", "Executive Compensation", "Ownership of our Stock", "Proposal 1: To Elect Three Class II and Two Class III Directors as Named in our Proxy Statement", "Proposal 3: To Provide an Advisory Vote to Approve the Compensation of our Named Executive Officers", and "Transactions with Related Persons, Promoters and Certain Control Persons", and which is available at:
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000937556/000110465925027887/tm259245-2_def14a.htm, and Masimo's Current Report on Form 8-K filed with the SEC on June 12, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000937556/000093755625000091/masi-20250606.htm, and Masimo's Current Report on Form 8-K filed with the SEC on August 19, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0000937556/000093755625000127/masi-20250818.htm. Information about Danaher's directors and executive officers is set forth in Danaher's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 20, 2025 under the heading entitled "Information About Our Executive Officers", and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000043/dhr-20241231.htm, and Danaher's Proxy Statement on Schedule 14A for its 2025 Annual Meeting of Stockholders, which was filed with the SEC on March 26, 2025, including under the headings entitled "Board of Directors and Committees of the Board," "2024 Annual Executive Compensation," "Beneficial Ownership of Danaher Common Stock by Directors, Officers and Principal Shareholders," "Proposal 1 - Election of Directors," "Proposal 3 - Advisory Vote on Named Executive Officer Compensation," and "Certain Relationships and Related Transactions," and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000081/dhr-20250326.htm, and Danaher's Current Report on Form 8-K filed with the SEC on July 24, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000155/dhr-20250721.htm, and Danaher's Current Report on Form 8-K filed with the SEC on July 31, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000172/dhr-20250728.htm, and Danaher's Current Report on Form 8-K filed with the SEC on November 6, 2025, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361625000198/dhr-20251106.htm, and Danaher's Current Report on Form 8-K filed with the SEC on February 5, 2026, including under the heading "Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." and which is available at: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000313616/000031361626000058/dhr-20260205.htm. To the extent holdings of Masimo's securities by its directors or executive officers have changed since the amounts set forth in such 2025 proxy statement, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, which are available at https://www.sec.gov/edgar/browse/?CIK=937556&owner=exclude. Additional information concerning the interests of Masimo's participants in the solicitation, which may, in some cases, be different than those of Masimo's stockholders generally, will be set forth in Masimo's proxy statement relating to the Transaction when it becomes available.CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts included in this communication that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements, including, in particular, statements about the expected timing, completion and effects or benefits of the Transaction. These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: (i) uncertainties as to the timing of the Transaction; (ii) the risk that the Transaction may not be completed on the anticipated terms in a timely manner or at all; (iii) the failure to satisfy any of the conditions to the consummation of the Transaction, including receiving, on a timely basis or otherwise, the required approval of the Transaction by Masimo's stockholders; (iv) the possibility that competing offers or acquisition proposals for Masimo will be made; (v) the possibility that any or all of the various conditions to the consummation of the Transaction may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, including in circumstances which would require Masimo to pay a termination fee; (vii) the effect of the announcement or pendency of the transactions contemplated by the merger agreement on Masimo's or Danaher's ability to retain and hire key personnel, their ability to maintain relationships with their customers, suppliers and others with whom they do business, or their operating results and businesses generally; (viii) risks related to diverting management's attention from Masimo's or Danaher's ongoing business operations; (ix) the risk that stockholder litigation in connection with the transactions contemplated by the merger agreement may result in significant costs of defense, indemnification and liability; (x) certain restrictions during the pendency of the Transaction that may impact Masimo's or Danaher's ability to pursue certain business opportunities or strategic transactions; (xi) the risk that any announcements relating to the Transaction could have adverse effects on the market price of Masimo's or Danaher's common stock, including if the proposed transaction is not consummated; (xii) risks that the benefits of the Transaction are not realized when and as expected; (xiii) legislative, regulatory and economic developments; and (xiv) other factors discussed in the "Risk Factors" sections of Masimo's and Danaher's most recent periodic and current reports filed with the SEC, all of which you may obtain for free on the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.NO OFFER OR SOLICITATION
This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. 



View original content:https://www.prnewswire.com/news-releases/danaher-to-acquire-masimo-corporation-302689266.htmlSOURCE Danaher Corporation

Original: Danaher To Acquire Masimo Corporation

Danaher Tops Q4 Forecasts, Bioprocessing Momentum Drives ResultsJanuary 28, 2026 1:39 PM
IH Market News
Danaher Corporation (NYSE:DHR) reported fourth-quarter results that exceeded market expectations, supported by solid performance across its healthcare and life sciences portfolio, with particular strength in bioprocessing.The company posted adjusted earnings of $2.23 per share for the quarter, ahead of analysts’ consensus estimate of $2.14. Revenue came in at $6.84 billion, topping forecasts of $6.79 billion and representing year-on-year growth of 4.5%. On a non-GAAP basis, core revenue increased 2.5%.Despite the earnings beat, Danaher shares edged 0.39% lower following the results.“We delivered a strong finish to the year with better-than-expected performance across our portfolio,” said Rainer M. Blair, president and chief executive officer. “We were particularly encouraged by continued strength in our bioprocessing business, along with improved momentum in Diagnostics and Life Sciences.”For the full year 2025, Danaher reported adjusted earnings per share of $7.80, up 4.5% from the prior year, on revenue of $24.6 billion, a 3.0% increase year on year. Operating cash flow totaled $6.4 billion, while non-GAAP free cash flow reached $5.3 billion.Looking ahead, the company expects low single-digit percentage growth in non-GAAP core revenue in the first quarter of 2026. For the full year, Danaher forecast core revenue growth of between 3% and 6%, with adjusted earnings per share in the range of $8.35 to $8.50. The midpoint of $8.425 comes in slightly above the analyst consensus estimate of $8.42.Danaher stock price

Original: Danaher Tops Q4 Forecasts, Bioprocessing Momentum Drives Results

Danaher Reports Fourth Quarter and Full Year 2025 ResultsJanuary 28, 2026 11:00 AM
PR Newswire (US)

WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.Key Fourth Quarter 2025 ResultsNet earnings were $1.2 billion, or $1.66 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 4.0% to $2.23.Revenues increased 4.5% year-over-year to $6.8 billion and non-GAAP core revenue increased 2.5% year-over-year.Operating cash flow was $2.1 billion and non-GAAP free cash flow was $1.8 billion.Key Full Year 2025 ResultsNet earnings were $3.6 billion, or $5.03 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 4.5% to $7.80.Revenues increased 3.0% year-over-year to $24.6 billion and non-GAAP core revenue increased 2.0% year-over-year.Operating cash flow was $6.4 billion and non-GAAP free cash flow was $5.3 billion.2025 Innovation HighlightsLaunched innovative new products and solutions, which strengthened Danaher's position as a trusted leader in life sciences and diagnostics.Cytiva expanded its Xcellerex X-platform bioreactor with 500L and 2,000L formats, helping customers improve yields while reducing the time and cost of biologic manufacturing.SCIEX introduced the ZenoTOF 8600 high-resolution mass spectrometer, helping researchers accelerate drug development timelines.Beckman Coulter Diagnostics expanded the assay menu of the DxI 9000 immunoassay platform, with notable progress in neurodegenerative disease assays.Cepheid received FDA clearance for its Xpert GI Panel, a rapid multiplex PCR test that detects 11 common gastrointestinal pathogens from a single patient sample.Rainer M. Blair, President and Chief Executive Officer, stated, "We delivered a strong finish to the year with better-than-expected performance across our portfolio.  We were particularly encouraged by continued strength in our bioprocessing business, along with improved momentum in Diagnostics and Life Sciences.  Our teams' disciplined execution also enabled us to exceed our fourth quarter margin, earnings, and cash flow expectations."Mr. Blair continued, "Looking ahead, we expect the gradual improvement in our end markets we saw through 2025 to continue, and we believe the combination of our differentiated portfolio, the power of the Danaher Business System, and the strength of our balance sheet positions Danaher for long-term value creation as we move into 2026 and beyond."First Quarter and Full Year 2026 OutlookThe Company does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) (except for estimated amortization of acquisition-related intangible assets of $1.7 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which for the first quarter and full year 2026 is estimated to increase sales by 3.5% and 1.0%, respectively, assuming the currency exchange rates in effect as of December 31, 2025) because the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control.  The impact of these additional elements could be material to our results computed in accordance with GAAP. For the first quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the low-single digit percent range year-over-year.For full year 2026, the Company expects that non-GAAP core revenue will increase in the 3% to 6% range year-over-year.  The Company is also initiating full year adjusted diluted net earnings per common share guidance in the range of $8.35 to $8.50.Conference Call and Webcast InformationDanaher will discuss its fourth quarter results and financial guidance for the first quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET.  The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations."  A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.The conference call can be accessed by dialing 800-245-3047 within the U.S. or by dialing +1 203-518-9765 outside the U.S. a few minutes before the 8:00 a.m. ET start and telling the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ425).  A replay of the conference call will be available shortly after the conclusion of the call and until February 11, 2026.  You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.  Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world.  Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies.  Focused on scientific excellence, innovation and continuous improvement, our approximately 60,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow.  Explore more at www.danaher.com.NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALSIn addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures.  Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).FORWARD-LOOKING STATEMENTS AND OTHER INFORMATIONStatements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the first quarter and full year 2026, the impact of recently-launched products, the anticipated improvement in end-markets, Danaher's long-term competitive positioning, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things: the impact of tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the healthcare industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the healthcare industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory changes or uncertainty, government shutdowns and military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2024 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2025.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.DANAHER CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Diluted Net Earnings Per Common Share and Adjusted Diluted Net Earnings Per Common Share 

 Three-Month Period Ended
Year Ended
December 31, 2025
December 31, 2024
December 31, 2025
December 31, 2024Diluted Net Earnings Per Common Share
From Continuing Operations (GAAP)$               1.66
$               1.49
$               5.03
$               5.29Amortization of acquisition-related intangible assetsA0.60
0.56
2.37
2.21Fair value net (gains) losses on investmentsB0.14
0.09
0.35
0.08ImpairmentsC0.02
0.06
0.78
0.36Gain on sale of a facilityD(0.02)
—
(0.02)
—Resolution of an acquisition contingencyE(0.01)
—
(0.01)
—Contract termination expenseF—
0.08
—
0.08Gain on a product line dispositionG—
—
(0.01)
—Acquisition-related itemsH—
—
—
0.03Tax effect of the above adjustmentsI(0.13)
(0.13)
(0.67)
(0.51)Discrete tax adjustmentsJ(0.04)
(0.01)
(0.02)
(0.07)Rounding0.01
—
—
0.01Adjusted Diluted Net Earnings Per
Common Share From Continuing
Operations (Non-GAAP)$               2.23
$               2.14
$               7.80
$               7.48 Notes to Above ReconciliationAAmortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):


Three-Month Period Ended
Year Ended
December 31, 2025
December 31, 2024
December 31, 2025
December 31, 2024Pretax$                428
$                408
$             1,697
$             1,631After-tax359
338
1,412
1,346

BNet (gains) losses, including impairments, on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above): 


Three-Month Period Ended
Year Ended
December 31, 2025
December 31, 2024
December 31, 2025
December 31, 2024Pretax$                 99
$                 64
$                248
$                 57After-tax75
48
188
39

CImpairment charges related to a facility in the Life Sciences segment recorded in the three-month period and year ended December 31, 2025 ($14 million pretax as reported in this line item, $11 million after-tax), technology, other intangible assets and a facility in the Biotechnology segment recorded in the year ended December 31, 2025 ($101 million pretax as reported in this line item, $69 million after-tax), a trade name in the Diagnostics segment recorded in the year ended December 31, 2025 ($15 million pretax as reported in this line item, $12 million after-tax), a trade name in the Life Sciences segment recorded in the year ended December 31, 2025 ($432 million pretax as reported in this line item, $328 million after-tax), a trade name in the Diagnostics segment recorded in the three-month period and year ended December 31, 2024 ($43 million pretax as reported in this line item, $32 million after-tax) and a trade name in the Life Sciences segment recorded in the year ended December 31, 2024 ($222 million pretax as reported in this line item, $169 million after-tax).

DGain on the sale of a facility in the three-month period and year ended December 31, 2025 ($11 million pretax as reported in this line item, $8 million after-tax).

EResolution of an acquisition contingency in the three-month period and year ended December 31, 2025 ($10 million pretax as reported in this line item, $8 million after-tax).

FLoss on the termination of a commercial agreement in the Diagnostics segment in the three-month period and year ended December 31, 2024 ($56 million pretax as reported in this line item, $56 million after-tax).

GGain on a product line disposition in the year ended December 31, 2025 ($9 million pretax as reported in this line item, $7 million after-tax).

HCosts incurred for the fair value adjustment to inventory related to the acquisition of Abcam plc ("Abcam") for the year ended December 31, 2024 ($25 million pretax as reported in this line item, $19 million after-tax).

IThis line item reflects the aggregate tax effect of all non-tax adjustments reflected in the preceding line items of the table.  In addition, the footnotes above indicate the after-tax amount of each individual adjustment item.  Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. 

JDiscrete tax adjustments and other tax-related adjustments for the three-month period ended December 31, 2025, include the impact of net discrete tax benefits of $26 million due principally to net discrete tax benefits resulting from the release of reserves for uncertain tax positions due to audit settlements and the expiration of statutes of limitation, partially offset by changes in estimates related to prior year tax filing positions and a valuation allowance recorded on certain tax credits in a foreign jurisdiction.  Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2025 include the impact of net discrete tax benefits of $14 million due principally to net discrete tax benefits resulting from the release of reserves for uncertain tax positions due to audit settlements and the expiration of statutes of limitation and the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change, partially offset by charges related to changes in estimates associated with prior period uncertain tax positions and valuation allowances recorded on foreign operating losses and tax credits in certain foreign jurisdictions.  Discrete tax adjustments for the three-month period ended December 31, 2024, include the impact of net discrete tax benefits of $4 million due principally to net discrete tax benefits resulting from the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates related to prior year tax filing positions, net of charges related to changes in estimates associated with prior period uncertain tax positions.  Discrete tax adjustments and other tax-related adjustments for the year ended December 31, 2024 include the impact of net discrete tax benefits of $49 million due principally to net discrete tax benefits resulting from excess tax benefits from stock compensation, the release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates related to prior year tax filing positions, net of charges related to changes in estimates associated with prior period uncertain tax positions. DANAHER CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(continued)
Sales Growth by Segment, Core Sales Growth (Decline) by Segment

% Change Three-Month Period Ended December 31, 2025 vs. Comparable
2024 Period


Segments
Total Company
Biotechnology
Life Sciences
DiagnosticsTotal sales growth (GAAP)4.5 %
9.0 %
2.5 %
3.0 %Impact of:






Acquisitions/divestitures0.5 %
— %
— %
1.0 %Currency exchange rates (2.5) %
(3.0) %
(2.0) %
(2.0) %Core sales growth (non-GAAP)2.5 %
6.0 %
0.5 %
2.0 %


% Change Year Ended December 31, 2025 vs. Comparable 2024 Period


Segments
Total Company
Biotechnology
Life Sciences
DiagnosticsTotal sales growth (GAAP)3.0 %
8.0 %
— %
1.5 %Impact of:






Acquisitions/divestitures— %
— %
(0.5) %
0.5 %Currency exchange rates (1.0) %
(1.5) %
(1.0) %
(0.5) %Core sales growth (decline) (non-GAAP)2.0 %
6.5 %
(1.5) %
1.5 % Other Supplemental Information($ in millions)


Three-Month Period Ended
December 31, 2025Cepheid respiratory revenue
~$500 Forecasted Core Sales Growth (Decline) by Segment and Adjusted Diluted Net Earnings Per Common Share.  

% Change Three-Month Period
Ending March 27, 2026 vs.
Comparable 2025 Period
% Change Year Ending December
31, 2026 vs. Comparable 2025
PeriodBiotechnology+High-single digit
~+6.0%Life SciencesFlat/ -Low-single digit
FlatDiagnostics-Low-single digit
+Low-single digitTotal Company core sales growth (non-GAAP)+Low-single digit
+3.0% - +6.0% 

Year Ending December 31, 2026Adjusted diluted net earnings per common share (non-GAAP)
$8.35 - $8.50 Supplemental Forward-Looking Information($ in millions)

Three-Month Period Ending March
27, 2026
Year Ending December 31, 2026Adjusted operating profit margin (non-GAAP)         ~28.5%

Impact of currency exchange rates on sales1~+3.5%
~+1.0%Corporate expense2~$(90)
~$(360)Interest expense, net3~$(45)
~($180)Effective tax rate~17.0%
~17.0%Average adjusted diluted shares~714.0
~717.0

1Impact of currency exchange rates on sales for the first quarter and full year 2026 assumes the currency exchange rates in effect as of December 31, 2025.2Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management's evaluation of reportable segment operating performance.3Interest expense, net is defined as interest expense net of interest income.  This line item is an assumption rather than a forecast.  The estimated interest expense, net is calculated assuming the currency exchange rates in effect as of December 31, 2025 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding. DANAHER CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(continued)
Operating Profit Margins and Year-Over-Year Core Operating Margin Changes




Segments

Total Company
Biotechnology
Life Sciences
DiagnosticsThree-Month Period Ended December 31, 2024 Operating
Profit Margins from Continuing Operations (GAAP)21.80 %
27.20 %
18.50 %
23.70 %
Fourth quarter 2025 impact from operating profit margins
of businesses that have been owned for less than one
year or were disposed of during such period and did not
qualify as discontinued operations(0.10)
—
(0.05)
(0.20)
Fourth quarter 2025 resolution of an acquisition
contingency in the Diagnostics segment0.15
—
—
0.35
Fourth quarter 2024 impairment charge related to a trade
name in the Diagnostics segment, net of a 2025
impairment charge related to a facility in the Life
Sciences segment0.45
—
(0.70)
1.60
Fourth quarter 2024 loss on the termination of a
commercial arrangement in the Diagnostics segment0.85
—
—
2.15Year-over-year core operating profit margin changes for
the fourth quarter 2025 (defined as all year-over-year
operating profit margin changes other than the changes
identified in the line items above) (non-GAAP)(1.15)
(0.60)
(1.65)
(1.40)Three-Month Period Ended December 31, 2025 Operating
Profit Margins from Continuing Operations (GAAP)22.00 %
26.60 %
16.10 %
26.20 %








Segments

Total Company
Biotechnology
Life Sciences
DiagnosticsYear Ended December 31, 2024 Operating Profit Margins
from Continuing Operations (GAAP)20.40 %
24.90 %
12.00 %
26.80 %
Full year 2025 impact from operating profit margins of
businesses that have been owned for less than one year
or were disposed of during such period and did not
qualify as discontinued operations(0.20)
—
(0.30)
(0.15)
Full year 2025 resolution of an acquisition contingency in
the Diagnostics segment0.05
—
—
0.10
Full year 2025 impairment charges related to trade
names in the Life Sciences and Diagnostics segments
and technology, other intangible assets and a facility in
the Biotechnology segment and a facility in the Life
Sciences segment, net of full year 2024 impairment
charges related to a trade name in each of the Life
Sciences and Diagnostics segments(1.20)
(1.30)
(3.05)
0.30
Full year 2024 loss on the termination of a commercial
arrangement in the Diagnostics segment0.25
—
—
0.60
Full year 2024 acquisition-related fair value adjustment to
inventory related to the acquisition of Abcam0.10
—
0.35
—Year-over-year core operating profit margin changes for
full year 2025 (defined as all year-over-year operating
profit margin changes other than the changes identified
in the line items above) (non-GAAP)(0.30)
2.00
(1.90)
(0.95)Year Ended December 31, 2025 Operating Profit Margins
from Continuing Operations (GAAP)19.10 %
25.60 %
7.10 %
26.70 % DANAHER CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(continued)
Cash Flow from Continuing Operations and Free Cash Flow from Continuing Operations and Related Measures($ in millions)

Three-Month Period Ended
Year Ended
December 31,
2025
December 31,
2024
December 31,
2025
December 31,
2024Total Cash Flows from Continuing Operations:






Total cash provided by operating activities from continuing
operations (GAAP)$        2,117
$        2,019
$        6,416
$        6,688Total cash used in investing activities from continuing
operations (GAAP)$          (384)
$          (694)
$       (1,196)
$       (1,981)Total cash provided by (used in) financing activities from
continuing operations (GAAP)$        1,322
$       (1,692)
$       (2,961)
$       (8,385)







Free Cash Flow from Continuing Operations:






Total cash provided by operating activities from continuing
operations (GAAP)$        2,117
$        2,019
$        6,416
$        6,688Less: payments for additions to property, plant & equipment
(capital expenditures) from continuing operations (GAAP)(371)
(516)
(1,156)
(1,392)Plus: proceeds from sales of property, plant & equipment
(capital disposals) from continuing operations (GAAP)23
1
33
13Free cash flow from continuing operations (non-GAAP)$        1,769
$        1,504
$        5,293
$        5,309







Operating Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Conversion Ratio
(GAAP)






Total cash provided by operating activities from continuing
operations (GAAP)$        2,117
$        2,019
$        6,416
$        6,688Net earnings from continuing operations (GAAP)1,183
1,086
3,600
3,899Operating cash flow from continuing operations to net
earnings from continuing operations conversion ratio1.79
1.86
1.78
1.72







Free Cash Flow from Continuing Operations to Net
Earnings from Continuing Operations Conversion Ratio
(non-GAAP)






Free cash flow from continuing operations from above (non-
GAAP)$        1,769
$        1,504
$        5,293
$        5,309Net earnings from continuing operations (GAAP)1,183
1,086
3,600
3,899Free cash flow from continuing operations to net earnings
from continuing operations conversion ratio (non-GAAP) 1.50
1.38
1.47
1.36
Note: The Company defines free cash flow as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing operations ("capital expenditures") plus the proceeds from sales of plant, property and equipment from continuing operations ("capital disposals").  All amounts presented above reflect only continuing operations.         Statement Regarding Non-GAAP MeasuresEach of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.  Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors:with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers;with respect to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; andwith respect to free cash flow from continuing operations and related non-GAAP cash flow measures (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of the FCF Measure is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).Management uses the non-GAAP measures referenced above to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company's executive compensation program.The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.Other Adjustments: With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to "restructuring charges" and "other adjustments", we exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and make comparisons of long-term performance difficult.With respect to core sales, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements.DANAHER CORPORATION AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS (unaudited)($ in millions, except per share amount)

As of December 31
2025
2024ASSETS


Current assets:


Cash and equivalents$          4,615
$          2,078Trade accounts receivable, less allowance for doubtful accounts of $114 as of
December 31, 2025 and $113 as of December 31, 20243,913
3,537Inventories2,489
2,330Prepaid expenses and other current assets1,739
1,552Total current assets12,756
9,497Property, plant and equipment, net5,531
4,990Other long-term assets4,209
3,990Goodwill43,151
40,497Other intangible assets, net17,817
18,568Total assets$        83,464
$        77,542



LIABILITIES AND STOCKHOLDERS' EQUITY


Current liabilities:


Notes payable and current portion of long-term debt$                2
$             505Trade accounts payable1,844
1,753Accrued expenses and other liabilities4,961
4,540Total current liabilities6,807
6,798Other long-term liabilities5,700
5,694Long-term debt18,416
15,500Stockholders' equity:


Common stock - $0.01 par value, 2.0 billion shares authorized; 886.9 million issued
and 706.9 million outstanding as of December 31, 2025; 884.3 million issued and
719.1 million outstanding as of December 31, 20249
9Additional paid-in capital17,194
16,727Treasury stock(11,353)
(8,163)Retained earnings46,891
44,188Accumulated other comprehensive income (loss)(207)
(3,218)Total Danaher stockholders' equity52,534
49,543Noncontrolling interests7
7Total stockholders' equity52,541
49,550Total liabilities and stockholders' equity$        83,464
$        77,542
This information is presented for reference only.  Final audited financial statements will include footnotes, which should be
referenced when available, to more fully understand the contents of this information.  DANAHER CORPORATION AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF EARNINGS (unaudited)($ and shares in millions, except per share amounts)

Three-Month Period Ended
Year Ended

December 31,
2025
December 31,
2024
December 31,
2025
December 31,
2024
Sales$          6,838
$          6,538
$        24,568
$        23,875
Cost of sales(2,872)
(2,648)
(10,045)
(9,669)
Gross profit3,966
3,890
14,523
14,206
Operating costs:







Selling, general and administrative expenses(2,026)
(2,023)
(8,235)
(7,759)
Research and development expenses(438)
(442)
(1,598)
(1,584)
Operating profit1,502
1,425
4,690
4,863
Nonoperating income (expense):







Other income (expense), net(87)
(63)
(222)
(56)
Interest expense(55)
(61)
(265)
(278)
Interest income13
14
30
117
Earnings from continuing operations before
income taxes1,373
1,315
4,233
4,646
Income taxes(190)
(229)
(633)
(747)
Net earnings from continuing operations1,183
1,086
3,600
3,899
Earnings from discontinued operations, net of
income taxes14
—
14
—
Net earnings1,197
1,086
3,614
3,899









Net earnings per common share from
continuing operations:







Basic$            1.67
$            1.50
$            5.05
$            5.33
Diluted$            1.66
$            1.49
$            5.03(a)$            5.29(a)Net earnings per common share from
discontinued operations:







Basic$            0.02
$               —
$            0.02
$               —
Diluted$            0.02
$               —
$            0.02
$               —
Net earnings per common share:







Basic$            1.69
$            1.50
$            5.07
$            5.33
Diluted$            1.68
$            1.49
$            5.05(a)$            5.29(a)Average common stock and common
equivalent shares outstanding:







Basic707.3
722.7
712.7
731.0
Diluted711.0
728.2
716.1
737.2

(a)  Net earnings per common share amount for the relevant three-month periods do not add to the full year period amount due to rounding.
This information is presented for reference only.  Final audited financial statements will include footnotes, which should be
referenced when available, to more fully understand the contents of this information. DANAHER CORPORATION AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)($ in millions)

Year Ended December 31
2025
2024Cash flows from operating activities:


Net earnings$              3,614
$              3,899Less: earnings from discontinued operations, net of income taxes(14)
—Net earnings from continuing operations3,600
3,899Noncash items:


Depreciation750
721Amortization of intangible assets1,697
1,631Amortization of acquisition-related inventory fair value step-up—
25Stock-based compensation expense298
288Investment losses, pretax gain on sale of product line and other228
57Impairment charges562
265Change in deferred income taxes(440)
(483)Change in trade accounts receivable, net(216)
331Change in inventories(58)
147Change in trade accounts payable9
19Change in prepaid expenses and other assets(55)
274Change in accrued expenses and other liabilities41
(486)Total operating cash provided by continuing operations6,416
6,688Cash flows from investing activities:


Cash paid for acquisitions—
(558)Payments for additions to property, plant and equipment(1,156)
(1,392)Proceeds from sales of property, plant and equipment33
13Payments for purchases of investments(127)
(331)Proceeds from sales of investments12
253Proceeds from sale of product line9
—All other investing activities33
34Total cash used in investing activities from continuing operations(1,196)
(1,981)Cash flows from financing activities:


Proceeds from the issuance of common stock in connection with stock-based
compensation85
162Payment of dividends(878)
(768)Net (repayments of) proceeds from borrowings (maturities of 90 days or less)(11)
5Borrowings (maturities longer than 90 days)1,556
—Repayments of borrowings (maturities longer than 90 days)(500)
(1,674)Payments for repurchase of common stock(3,088)
(5,979)All other financing activities(125)
(131)Net cash used in financing activities for continuing operations(2,961)
(8,385)Effect of exchange rate changes on cash and equivalents278
(108)Net change in cash and equivalents2,537
(3,786)Beginning balance of cash and equivalents2,078
5,864Ending balance of cash and equivalents$              4,615
$              2,078
This information is presented for reference only.  Final audited financial statements will include footnotes, which should be
referenced when available, to more fully understand the contents of this information. DANAHER CORPORATION AND SUBSIDIARIESSEGMENT INFORMATION (unaudited)($ in millions)

Three-Month Period Ended
Year Ended

December 31, 2025
December 31, 2024
December 31, 2025
December 31, 2024
Sales (GAAP):







Biotechnology$              2,033
$              1,869
$              7,293
$              6,759
Life Sciences2,085
2,032
7,334
7,329
Diagnostics2,720
2,637
9,941
9,787
Total Company$              6,838
$              6,538
$            24,568
$            23,875









Operating Profit (GAAP):







Biotechnology$                  540
$                  508
$              1,864
$              1,685
Life Sciences336
376
520
879
Diagnostics713
624
2,650
2,625
Other(87)
(83)
(344)
(326)
Total Company$              1,502
$              1,425
$              4,690
$              4,863









Operating Profit Margins (GAAP):







Biotechnology26.6 %
27.2 %
25.6 %
24.9 %
Life Sciences16.1 %
18.5 %
7.1 %
12.0 %
Diagnostics26.2 %
23.7 %
26.7 %
26.8 %
Total Company22.0 %
21.8 %
19.1 %
20.4 %









Amortization of Intangible Assets (GAAP):







Biotechnology$                  230
$                  213
$                  902
$                  863
Life Sciences151
148
604
576
Diagnostics47
47
191
192
Total Company$                  428
$                  408
$              1,697
$              1,631









Other Operating Profit Adjustments4:







Biotechnology$                    —
$                    —
$                  101C$                    —
Life Sciences14C—
446C247C, HDiagnostics(10)E99C, F5C, E99C, FTotal Company$                      4
$                    99
$                  552
$                  346









Adjusted Operating Profit (non-GAAP)5:







Biotechnology$                  770
$                  721
$              2,867
$              2,548
Life Sciences501
524
1,570
1,702
Diagnostics750
770
2,846
2,916
Other(87)
(83)
(344)
(326)
Total Company$              1,934
$              1,932
$              6,939
$              6,840









Depreciation (GAAP):







Biotechnology$                    39
$                    38
$                  149
$                  151
Life Sciences48
44
185
167
Diagnostics106
102
407
394
Other2
3
9
9
Total Company$                  195
$                  187
$                  750
$                  721

4 Refer to the Reconciliation of Adjusted Diluted Net Earnings per Common Share for footnotes containing descriptions of the components of Other
Operating Profit Adjustments.  All Other Operating Profit Adjustments are included within Selling, general and administrative expenses within the
Consolidated Statements of Earnings, other than $14 million recorded in the three-month period ended December 31, 2025 in the Life Sciences
segment, $29 million recorded in the year ended December 31, 2025 in the Life Sciences and Biotechnology segments and $25 million recorded in the
year ended December 31, 2024 in the Life Sciences segment, which are recorded within Cost of sales.5 Adjusted Operating Profit (non-GAAP) is defined as Operating Profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating
Profit Adjustments (as defined).
This information is presented for reference only.  Final audited financial statements will include footnotes, which should be
referenced when available, to more fully understand the contents of this information. 



View original content:https://www.prnewswire.com/news-releases/danaher-reports-fourth-quarter-and-full-year-2025-results-302671883.htmlSOURCE Danaher Corporation

Original: Danaher Reports Fourth Quarter and Full Year 2025 Results

DHR Rocks ...

Just realized the div cut was because of the Veralto spinoff last October. So no big deal.

"Danaher Cuts Quarterly Dividend to 24 Cents"

Danaher lowered its quarterly cash dividend to 24 cents a share from 27 cents.
The new payout, equal to 96 cents a year, represents an annual yield of 0.4% based on Tuesday's closing price of $219.44.
The health-care and laboratory-supply company said the dividend is payable on Jan. 26, 2024, to shareholders of record on Dec. 29.

https://www.marketscreener.com/quote/stock/DANAHER-CORPORATION-12295/news/Danaher-Cuts-Quarterly-Dividend-to-24-Cents-45507051/

Danaher Corp Quarterly Dividends

Date Dividends
Jun 29, 2023 0.27 Dividend
Mar 30, 2023 0.27 Dividend
Dec 29, 2022 0.25 Dividend
Sep 29, 2022 0.25 Dividend
Jun 23, 2022 0.25 Dividend
Mar 24, 2022 0.25 Dividend
Dec 29, 2021 0.21 Dividend
Sep 29, 2021 0.21 Dividend
Jun 24, 2021 0.21 Dividend
Mar 25, 2021 0.21 Dividend
Dec 24, 2020 0.18 Dividend
Sep 25, 2020 0.18 Dividend
Jun 25, 2020 0.18 Dividend
Mar 26, 2020 0.18 Dividend
Dec 26, 2019 0.17 Dividend
Sep 26, 2019 0.17 Dividend
Jun 27, 2019 0.17 Dividend
Mar 28, 2019 0.17 Dividend
Dec 27, 2018 0.16 Dividend
Sep 27, 2018 0.16 Dividend

"Danaher ups dividend by 8% to $0.27"

"Danaher (NYSE:DHR) declares $0.27/share quarterly dividend, 8% increase from prior dividend of $0.25.
Forward yield 0.43%
Payable April 28; for shareholders of record March 31; ex-div March 30, 2023."

https://seekingalpha.com/news/3939480-danaher-corporation-declares-0_27-dividend

"Danaher Stock Is Soaring. Earnings Surged on Covid-Test Success."

"Danaher DHR +7.93% produced strongly upside second-quarter results, and shares are up a lot in early Thursday trading. The company’s Covid-testing business was an unexpected surprise."

https://www.barrons.com/articles/danaher-earnings-stock-covid-51658420631

Substantial Div Increase for Danaher

Date Dividends
Mar 24, 2022 0.25 Dividend
Dec 29, 2021 0.21 Dividend
Sep 29, 2021 0.21 Dividend
Jun 24, 2021 0.21 Dividend
Mar 25, 2021 0.21 Dividend
Dec 24, 2020 0.18 Dividend
Sep 25, 2020 0.18 Dividend
Jun 25, 2020 0.18 Dividend
Mar 26, 2020 0.18 Dividend
Dec 26, 2019 0.17 Dividend
Sep 26, 2019 0.17 Dividend
Jun 27, 2019 0.17 Dividend
Mar 28, 2019 0.17 Dividend
Dec 27, 2018 0.16 Dividend
Sep 27, 2018 0.16 Dividend
Jun 28, 2018 0.16 Dividend
Mar 28, 2018 0.16 Dividend
Dec 28, 2017 0.14 Dividend

Thanks for those links. Recent advancements in generator technology are interesting. Over the years, especially when storms make headlines, I've thought about getting a generator for my home. But they're costly and need fueling and maintenance. One more thing to worry about. Where I live significant outages are rare.

Wow, Danaher hitting $325.

Bar, Danaher has always been a great long term stock, though the Covid related aspect has moved it into the 'momentum play' realm. Earnings growth of 92%, rev growth 36%, PE 43 (per Yahoo), this likely won't be sustainable forever for a company the size of Danaher, although the high growth and valuation may continue for some time. A great long term stock but high valuation.

Generac is even pricier, but 1/10 the size and should keep growing for many years. Even with the recent class action lawsuits, the stock is back near the highs again. They also have the energy storage and smart grid aspects -


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164787724

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164485279

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165681364


These are both great stocks. The market needs a decent pullback, but the Fed 'juice' has prevented even a 5% correction. So I'm mostly on the sidelines for now. I would prefer a buy/hold forever strategy like you have, but am increasingly averse to capital loss, so currently overweight in cash, T-Bills, and shorter term bonds.

Generac, with a market cap of $28 billion, joined the S&P 500 a few months ago, I see. Previously it was one of the largest firms in the S&P Midcap 400 index.

Generac top #7 holding be weight for SPX pure growth ETF. The other day was just looking over what constitutes pure growth vs pure value investments and noticed Generac was on there.

Interesting. Because of the hurricane I was just reviewing your Generac which I always considered to be a sensible speculation. Before Generac rose so much in the past couple of years, it was too small for my taste and it paid no dividend. I figured it didn't have much of a moat as many firms around the world make or could make generators.

I don't add many new stocks, relying mostly on index funds. Danaher is my most recent addition, from several years ago and it's certainly a honey of an investment.

Hi Bar, OT - >> General Stock Ideas <<

I-Hub converted it into a 'Premium' board after an extended heated argument over the Covid vaccines (a touchy topic these days). I was not the official moderator on that board, so was unable to effectively police the board. So I think the idea was to basically shut down activity on that board by making it 'Premium'.

Anyway, I moved over to the 'Awesome Stocks' board (link below), and am trying to keep things civil. You are welcome to post anytime :o) -


https://investorshub.advfn.com/Awesome-Stocks-36107/

Is your main General Stock Ideas board for IHUB subscribers only now? Did you mean to make that change?

$324 DHR wow

>>> Is Danaher a Buy in a Post-Pandemic World?

Analyzing the investment case for buying stock in the high-flying life sciences and diagnostics company.


Motley Fool

by Lee Samaha

Aug 4, 2021


https://www.fool.com/investing/2021/08/04/is-danaher-a-buy-in-a-post-pandemic-world/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article


Key Points

The pandemic has enhanced the company's long-term growth potential.

Current trading continues to exceed expectations.

Non-COVID-19 related revenue is back in growth mode.


Life science and diagnostics company Danaher (NYSE:DHR) is one of the big winners from the COVID-19 pandemic. Its diagnostic tests help detect the coronavirus, and its life sciences tools help medical bodies research and develop vaccines and therapies for it.

That said, what happens to the company's growth rate after the pandemic is over? Are investors in the stock about to be left holding a stock trading on a high valuation that's just about to see earnings growth prospects deteriorate?

Three reasons Danaher can keep on delivering

I think there's reason to believe that Danaher can keep growing at a very healthy clip, even in a post-pandemic environment.

Current earnings momentum is robust across all its businesses, COVID-19 related and non-COVID-19 alike.

Management's guidance for non-COVID-19 related revenue growth in 2021 has been upgraded and demonstrates underlying strength in the business.
The pandemic has strengthened the company's core business and growth prospects.

Strong earnings momentum

The company recently delivered its second-quarter earnings, and it managed to sail past management's previous guidance. For example, management had previously forecast second-quarter core revenue growth would come in within the mid-20% range, but it came in at 31.5%. As such, management upgraded its expectation for full-year core revenue growth from "high teens" to "approximately 20%."

As you can see below, the life sciences and diagnostics segments continue a powerful run, boosted by the pandemic (more on that in a moment), and the environmental and applied solutions (EAS) business is also back in growth mode. For reference, life sciences contributed $2.3 billion of operating profit in the first half compared to $1.3 billion from diagnostics and $565 million from EAS.

EAS is a collection of water quality and product ID businesses. During the earnings call, CEO Rainer Blair noted that both business platforms grew strongly in the quarter as the reopening of the economy increased sales and order rates as customers were investing in "larger projects" again.

Non-COVID-19 growth is strong too

The burning question on everybody's lips is, what kind of growth rate can investors expect after the pandemic? To help answer it, Danaher's management breaks out its guidance into COVID-19 related revenue and its "base business." As noted earlier, the full-year core revenue growth guidance was raised to "approximately 20%."

Going into more detail on the matter, Blair said "We anticipate that COVID related revenue tailwinds will be an approximately 10% contribution to the core revenue growth rate, and in our base business, we now expect that core revenue will be up 10% for the full year, an increase from our prior expectation of high single-digit."

In other words, the ramp up in the guidance primarily comes down to an increase in the guidance from the base business. That bodes well for Danaher's post-pandemic growth prospects.

The pandemic has structurally enhanced Danaher's growth

This is a subtle and critical point to understand. It's not just that the pandemic provided a temporary boost to Danaher's prospects. In life sciences, the investment made worldwide in vaccine and therapeutic science to combat the coronavirus is likely to spill out into broader-based research that can benefit Danaher for years to come.

Meanwhile, Blair outlined that monoclonal antibody-based therapies in development have increased 50% "from just five years ago." Turning back to COVID-19, there's always the possibility that a third booster shot and wide-scale vaccination of children will provide a near-term boost to Danaher's sales.

Danaher has increased its installed base of diagnostic platforms by over 40% since the pandemic started. That's important because the diagnostics business works based on the "razor/razor blade" business model. In other words, more platform sales lead to more opportunities for Danaher to sell new tests into the installed base. For example, Blair pointed out that assays (tests) for sexual health and hospital-acquired infections were up 30% in the second quarter. Also, Danaher is continually working on new assays.

Danaher is ramping up capital spending from $790 million in 2020 to around $1.5 billion in 2021, partly to build on the growth in assay development and fuel growth in the Cytiva biopharma business bought from General Electric in 2020.

Is Danaher a buy?

The exciting thing about Danaher's valuation is that it trades on roughly the same enterprise value (market cap plus net debt)-to-earnings before interest, taxation, depreciation, and amortization (EBITDA) valuation as it did before the pandemic started.

Therefore, if you believe in relative valuations, then Danaher is an attractive stock because the pandemic has enhanced its long-term growth potential. On the other hand, it's still a pretty hefty valuation to trade on, and cautious investors might want to wait for a dip to buy into a very attractive company.

<<<

I will definitely find those other 17 and add them to my portfolio just like DHR, one by one. Eventually will get them all. I trust your success.

The penny junk is entertainment to get me through the daily 9-6 at the office. You win some. You lose some.

DHR touched another high. Amazing performance.

Have a good weekend.

That's a scary thought. Who did you follow into all your crumbling penny stocks?

At least you're improving. DHR is a blue chip with a market cap of $220 billion. Be aware that I only buy blue chips and I have a profit in every one of the ~17 individual stocks I own. Of course my average holding period can be measured in decades.

I make money with my stocks.

I followed you to find this stock. Impressive indeed. Thank you. Will accumulate when possible.

Danaher. Very impressive. Just touched another record high.

312.70 this hits new highs every day. Is this normal?

Danaher 10-year Chart

DHR Split History
Date Ratio
01/23/1995 2 for 1
06/01/1998 2 for 1
05/21/2004 2 for 1
06/14/2010 2 for 1
07/05/2016 1319 for 1000

Forward split please, soon.

Bought more.

Bought in today for long term hold. Solid stock here. DHR

$254. Another record high for DHR

DHR— So nice they surpassed estimates yay!! Thanks!

"Danaher (NYSE-DHR) Q1 Earnings and Revenues Surpass Estimates"

"Danaher (DHR) came out with quarterly earnings of $2.52 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 50.90%. A quarter ago, it was expected that this industrial and medical device maker would post earnings of $1.84 per share when it actually produced earnings of $2.08, delivering a surprise of 13.04%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times."

https://finance.yahoo.com/news/danaher-dhr-q1-earnings-revenues-113011852.html

This is interesting in light of recent price action.

https://www.quantiumresearch.co.uk/post/potential-double-top-formation-for-danaher-corp

Danaher Significant Payout Increase.

"DHR designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates in the Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions segments. DHR was founded in 1969 and is headquartered in Washington, the District of Columbia.

On Feb 23, DHR declared a quarterly dividend of 21¢ per share.
This is an increase of 16.67% from the prior dividend of 18¢.
Payable Apr 30, to shareholders of record on Mar 26; ex-div: Mar 25."

https://seekingalpha.com/article/4410154-dividend-increases-february-20minus-26-2021

Thanks for the info about hedge funds owning it. I see that it isn’t cheap. Thanks for the great info! Will consider it! Enjoy a great day and stay warm!